[6-K] Haleon plc American Current Report (Foreign Issuer)
Haleon has announced a significant share buyback transaction as part of its program launched on March 28, 2025.
Rhea-AI Filing Summary
Haleon has announced a significant share buyback transaction as part of its program launched on March 28, 2025. On June 23, 2025, the company purchased 1,008,610 ordinary shares for cancellation at prices ranging from 381.50p to 387.90p per share, with a volume-weighted average price of 385.10p.
Following the transaction, Haleon's registered share capital consists of 8,990,548,799 ordinary shares, with 4,080,205 held as treasury shares. The total number of voting rights is now 8,986,468,594, a figure relevant for shareholder disclosure requirements under FCA regulations.
Haleon, a global consumer health leader listed on LSE/NYSE (HLN), maintains a portfolio across six major categories including Oral Health, VMS, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Key brands include Advil, Centrum, Sensodyne, and Voltaren.
Positive
- Haleon executed a significant share buyback, purchasing 1,008,610 shares at a volume-weighted average price of 385.10p, demonstrating confidence in company value and returning capital to shareholders
- The company maintains a strong market position as a global leader in consumer health with a portfolio of trusted brands including Advil, Centrum, Sensodyne, and Voltaren
Negative
- None.
FAQ
What are HLN's major product categories as mentioned in the filing?
Haleon's product portfolio spans six major categories: Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Key brands include Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2025
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
|
|
Form
20-F ☒
|
Form
40-F ☐
|
|
EXHIBIT INDEX
|
Exhibit
Number
|
Description
|
|
99.1
|
24 June
2025 - “Transaction in Own Shares”
|
99.1
Haleon plc: Transaction in own shares
24 June 2025: Haleon plc (the "Company" or
"Haleon") today announces the purchase of the following number of
ordinary shares of £0.01 each in the Company (the "Shares")
for cancellation under its share buyback programme announced on 28
March 2025 (the "Buyback Programme").
|
Date
of purchase:
|
23 June 2025
|
|
Number
of Shares purchased:
|
1,008,610
|
|
Highest
price paid per share (p):
|
387.90
|
|
Lowest
price paid per share (p):
|
381.50
|
|
Volume
weighted average price paid per share (p):
|
385.10
|
Following the settlement of the above, the Company's registered
share capital is 8,990,548,799 ordinary shares of £0.01 each,
of which 4,080,205 are held as treasury shares. Therefore, the
number of ordinary shares with voting rights is 8,986,468,594 and
this figure may be used by shareholders to determine if they are
required to notify their interest, or a change to their interest,
in Haleon under the FCA's Disclosure Guidance and Transparency
Rules.
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014
as it applies in the UK (the Market Abuse Regulation), a full
breakdown of the individual trades is available at the link
below:
http://www.rns-pdf.londonstockexchange.com/rns/0619O_1-2025-6-23.pdf
This announcement does not constitute, or form part of, an offer or
any solicitation of an offer for securities in any
jurisdiction.
This announcement and individual trade breakdown will also be
available on the Company's website at: www.haleon.com/investors.
Enquiries
|
Investors
|
|
Media
|
|
|
Jo Russell
|
+44 7787 392441
|
Zoë Bird
|
+44 7736 746167
|
|
Rakesh Patel
|
+44 7552 484646
|
Victoria Durman
|
+44 7894 505730
|
|
Emma White
|
+44 7823 523562
|
|
|
|
Email: investor-relations@haleon.com
|
|
Email: corporate.media@haleon.com
|
|
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with
a purpose to deliver better everyday health with humanity. Haleon's
product portfolio spans six major categories - Oral Health,
Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory
Health, Digestive Health and Therapeutic Skin Health and Other. Its
long-standing brands - such as Advil, Centrum, Otrivin,
Panadol, parodontax, Polident, Sensodyne,
Theraflu and Voltaren - are built on trusted science, innovation
and deep human understanding.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
|
Date: June 24,
2025
|
By:
|
/s/
Amanda Mellor
|
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|